Phio Pharmaceuticals (NASDAQ:PHIO) is up 14% premarket after announcing positive data from in vivo
studies that show strong antitumoral efficacy with several of its
INTASYL pipeline programs, including PH-762, PH-894 and PH-804.
These results show that intratumoral delivery of
INTASYL compounds inhibited tumor growth by overcoming the
immunosuppressive tumor microenvironment (TME) as shown by changes in T
cell composition and activation.
These data were presented during the ASCO 2020 Virtual Scientific Program.
PH-762, PH-894 and PH-804 are INTASYL compounds
designed to silence the expression of PD-1, BRD4 and TIGIT,
respectively, which are proteins linked to reduced immune cell function
in cancer patients.
https://seekingalpha.com/news/3578616-phio-pharmaplus-14-on-positive-data-from-intasyl-programs
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.